MX2012010918A - Analogos para el tratamiento o prevencion de infecciones por flavivirus. - Google Patents

Analogos para el tratamiento o prevencion de infecciones por flavivirus.

Info

Publication number
MX2012010918A
MX2012010918A MX2012010918A MX2012010918A MX2012010918A MX 2012010918 A MX2012010918 A MX 2012010918A MX 2012010918 A MX2012010918 A MX 2012010918A MX 2012010918 A MX2012010918 A MX 2012010918A MX 2012010918 A MX2012010918 A MX 2012010918A
Authority
MX
Mexico
Prior art keywords
sub
analogues
prevention
treatment
flavivirus infections
Prior art date
Application number
MX2012010918A
Other languages
English (en)
Inventor
Youssef L Bennani
Sanjoy Kumar Das
Oswy Z Pereira
Constantin Yannopoulos
Laval Chan Chun Kong
Carl Poisson
John Maxwell
Caroline Cadilhac
Bingcan Liu
Real Denis
Guy Falardeau
Simon Giroux
James Henderson
Mark A Morris
Jagadeeswar T Reddy
Louis Vaillancourt
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2012010918A publication Critical patent/MX2012010918A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/22—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms directly attached to ring nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Los compuestos representados por la formula I o sales farmacéuticamente aceptables de estos, en donde A, B, ´B, X, Y, R1, R2, R3, R3, R´3, R4, R4´, R5, m, n,, o p son como se definen en la presente descripción, son útiles para tratar las infecciones virales por flaviviridae.
MX2012010918A 2010-03-24 2011-03-24 Analogos para el tratamiento o prevencion de infecciones por flavivirus. MX2012010918A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31698810P 2010-03-24 2010-03-24
PCT/US2011/029825 WO2011119853A1 (en) 2010-03-24 2011-03-24 Analogues for the treatment or prevention of flavivirus infections

Publications (1)

Publication Number Publication Date
MX2012010918A true MX2012010918A (es) 2013-01-18

Family

ID=43971841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010918A MX2012010918A (es) 2010-03-24 2011-03-24 Analogos para el tratamiento o prevencion de infecciones por flavivirus.

Country Status (9)

Country Link
US (1) US8779156B2 (es)
EP (1) EP2550267A1 (es)
JP (1) JP2013522375A (es)
CN (1) CN102869657A (es)
AR (1) AR080725A1 (es)
AU (1) AU2011232331A1 (es)
CA (1) CA2794145A1 (es)
MX (1) MX2012010918A (es)
WO (1) WO2011119853A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011006332A (es) 2008-12-23 2011-06-27 Abbott Lab Compuestos antivirales.
EP2367823A1 (en) 2008-12-23 2011-09-28 Abbott Laboratories Anti-viral compounds
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
PT2368890E (pt) 2009-06-11 2013-07-17 Abbvie Bahamas Ltd Inibidores do vírus da hepatite c
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
NZ597982A (en) 2009-09-04 2013-01-25 Glaxosmithkline Llc CHEMICAL COMPOUNDS for treating Hepatitis C virus
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
KR20140053166A (ko) 2011-07-09 2014-05-07 선샤인 레이크 파르마 컴퍼니 리미티드 C형 간염 바이러스 억제제로서 스피로 화합물
ES2558608T3 (es) * 2011-12-28 2016-02-05 Janssen Sciences Ireland Uc Derivados hetero-bicíclicos como inhibidores del VHC
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI610916B (zh) 2012-08-03 2018-01-11 廣東東陽光藥業有限公司 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用
CN103848818B (zh) 2012-11-29 2017-03-15 广东东阳光药业有限公司 作为丙型肝炎抑制剂的并环化合物、药物组合物及它们在药物中的应用
CN103848821B (zh) 2012-11-29 2016-10-12 广东东阳光药业有限公司 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN104803989B (zh) 2014-01-23 2017-12-22 广东东阳光药业有限公司 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017023631A1 (en) 2015-08-06 2017-02-09 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2018232174A2 (en) * 2017-06-16 2018-12-20 Avalon Flaviviral Therapeutics (Hk) Limited Compositions and methods for treating flavivirus infections
US11096927B2 (en) 2018-12-19 2021-08-24 Florida State University Research Foundation, Inc. Anti-flavivirus compounds and methods of use
CA3223875A1 (en) * 2021-06-25 2022-12-29 Shigeru Matsuoka Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169880T3 (es) 1996-10-18 2002-07-16 Vertex Pharma Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c.
IL134233A0 (en) 1997-08-11 2001-04-30 Boehringer Ingelheim Ca Ltd Hepatitis c inhibitor peptide analogues
EP1003775B1 (en) 1997-08-11 2005-03-16 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptides
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SK13752001A3 (sk) 1999-12-27 2002-07-02 Japan Tobacco, Inc. Zlúčeniny s fúzovanými kruhmi a ich použitie ako liečiv
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AU2002248147B2 (en) 2000-11-20 2006-04-06 Bristol-Myers Squibb Company Hepatitis C tripeptide inhibitors
KR100828453B1 (ko) 2001-01-22 2008-05-13 머크 앤드 캄파니 인코포레이티드 Ｒｎａ 의존성 ｒｎａ 바이러스 폴리머라제의억제제로서의 뉴클레오시드 유도체
AU2002252183A1 (en) 2001-03-06 2002-09-19 Biocryst Pharmaceuticals, Inc. Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
EP1256628A3 (en) 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
JP4544857B2 (ja) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
AU2002337765A1 (en) 2001-09-26 2003-04-07 Bristol-Myers Squibb Company Compounds useful for treating hepatitus c virus
AU2002348414B2 (en) 2001-10-24 2009-10-01 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
PL373399A1 (en) 2002-04-11 2005-08-22 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
AU2003264038A1 (en) 2002-08-12 2004-02-25 Bristol-Myers Squibb Company Combination pharmaceutical agents as inhibitors of hcv replication
JP2006526011A (ja) 2003-04-11 2006-11-16 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ（特に、ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ）のインヒビター
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
KR20060052836A (ko) 2003-07-18 2006-05-19 버텍스 파마슈티칼스 인코포레이티드 세린 프로테아제, 특히 ｈｃｖ ｎｓ3-ｎｓ4ａ 프로테아제의억제제
TWI359147B (en) 2003-09-05 2012-03-01 Vertex Pharma Inhibitors of serine proteases, particularly hcv n
US20050119189A1 (en) 2003-09-18 2005-06-02 Cottrell Kevin M. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AU2005212257A1 (en) 2004-02-04 2005-08-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
EP1804821A4 (en) 2004-10-01 2009-07-15 Vertex Pharma INHIBITION OF HCV NS3-NS4A PROTEASE
US7964571B2 (en) * 2004-12-09 2011-06-21 Egen, Inc. Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases
US8143288B2 (en) 2005-06-06 2012-03-27 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7759495B2 (en) 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5173166B2 (ja) 2006-08-14 2013-03-27 スリーエム イノベイティブ プロパティズ カンパニー 粘着性フィルム剥離方法
US7741347B2 (en) * 2007-05-17 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7728027B2 (en) 2007-08-08 2010-06-01 Bristol-Myers Squibb Company Process for synthesizing compounds useful for treating hepatitis C
US8629171B2 (en) 2007-08-08 2014-01-14 Bristol-Myers Squibb Company Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt
PT2250163E (pt) 2008-02-12 2012-06-01 Bristol Myers Squibb Co Inibidores do vírus da hepatite c
PL2242752T3 (pl) 2008-02-13 2012-12-31 Bristol Myers Squibb Co Imidazolilobifenyloimidazole jako inhibitory wirusa zapalenia wątroby typu c
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7704992B2 (en) 2008-02-13 2010-04-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5100595B2 (ja) 2008-09-30 2012-12-19 シャープ株式会社 Ａｖ機器、サーバ、ａｖ機器の操作システムおよびａｖ機器の操作用プログラム
JP5268532B2 (ja) 2008-09-30 2013-08-21 株式会社日立ハイテクノロジーズ 試料計測方法、及び計測装置
JP5225240B2 (ja) 2008-10-01 2013-07-03 住友ゴム工業株式会社 タイヤ用ゴム組成物及びタイヤ
JP5762971B2 (ja) 2008-12-03 2015-08-12 プレシディオ ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ５ａの阻害剤
NZ593808A (en) 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
WO2010096462A1 (en) 2009-02-17 2010-08-26 Enanta Pharmaceuticals, Inc Linked diimidazole derivatives
TWI438200B (zh) 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
WO2010096777A1 (en) 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
CA2753382C (en) * 2009-02-27 2014-12-23 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US8101643B2 (en) * 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8507522B2 (en) * 2009-03-06 2013-08-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
GEP20146134B (en) 2009-03-27 2014-08-11 Merck Sharp & Dohme Inhibitors of hepatitis c virus replication
EP2410841A4 (en) 2009-03-27 2012-10-24 Presidio Pharmaceuticals Inc SUBSTITUTED BICYCLIC HCV INHIBITORS
WO2010111534A1 (en) 2009-03-27 2010-09-30 Presidio Pharmaceuticals, Inc. Fused ring inhibitors of hepatitis c
TWI476190B (zh) 2009-03-30 2015-03-11 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8796466B2 (en) * 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2541571C2 (ru) 2009-04-15 2015-02-20 Эббви Инк. Противовирусные соединения
WO2010122162A1 (en) 2009-04-24 2010-10-28 Tibotec Pharmaceuticals Diaryl ethers
CA2760205A1 (en) 2009-05-12 2010-11-18 Schering Corporation Fused tricyclic aryl compounds useful for the treatment of viral diseases
EP3626716A1 (en) * 2009-05-13 2020-03-25 Gilead Pharmasset LLC Antiviral compounds
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AU2010253791A1 (en) * 2009-05-29 2011-11-24 Merck Sharp & Dohme Corp. Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C
PT2368890E (pt) 2009-06-11 2013-07-17 Abbvie Bahamas Ltd Inibidores do vírus da hepatite c
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
WO2011009084A2 (en) 2009-07-16 2011-01-20 Vertex Pharmaceuticals Incorporated Benzimidazole analogues for the treatment or prevention of flavivirus infections
NZ597982A (en) 2009-09-04 2013-01-25 Glaxosmithkline Llc CHEMICAL COMPOUNDS for treating Hepatitis C virus
WO2011050146A1 (en) 2009-10-23 2011-04-28 Glaxosmithkline Llc Chemical compounds
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110274648A1 (en) * 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075615A1 (en) 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
SG181614A1 (en) * 2009-12-24 2012-07-30 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
EP2528436A4 (en) 2010-01-25 2013-07-10 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
CN102858157A (zh) 2010-03-04 2013-01-02 埃南塔制药公司 作为hcv复制的抑制剂的组合药物活性剂
ES2558554T3 (es) 2010-03-09 2016-02-05 Merck Sharp & Dohme Corp. Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
EP2555622A4 (en) 2010-04-09 2013-09-18 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
WO2011150243A1 (en) 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US8778938B2 (en) 2010-06-04 2014-07-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011156543A2 (en) 2010-06-09 2011-12-15 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a protein
CN103153986B (zh) 2010-08-04 2014-11-05 百时美施贵宝公司 丙型肝炎病毒抑制剂
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8697704B2 (en) 2010-08-12 2014-04-15 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
MX2013002927A (es) 2010-09-24 2013-05-30 Bristol Myers Squibb Co Inhibidores del virus de la hepatitis c.
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
KR20140001879A (ko) 2010-09-29 2014-01-07 머크 샤프 앤드 돔 코포레이션 Ｃ형 간염 바이러스 감염을 치료하기 위한 테트라시클릭 인돌 유도체
WO2012041227A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds for treating hepatitis c viral infection
WO2012040924A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Fused tetracyclic heterocycle compounds and methods of use thereof for treatment of viral diseases
WO2012040923A1 (en) 2010-09-29 2012-04-05 Merck Sharp & Dohme Corp. Tetracyclic indole derivatives and methods of use thereof for the treatment of viral diseases
NZ609564A (en) 2010-10-26 2015-06-26 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
WO2012122716A1 (en) 2011-03-17 2012-09-20 Merck Sharp & Dohme Corp. Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US8809313B2 (en) 2011-05-27 2014-08-19 Achillion Pharmaceuticals, Inc. Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating HCV infections

Also Published As

Publication number Publication date
WO2011119853A1 (en) 2011-09-29
EP2550267A1 (en) 2013-01-30
CN102869657A (zh) 2013-01-09
JP2013522375A (ja) 2013-06-13
AR080725A1 (es) 2012-05-02
CA2794145A1 (en) 2011-09-29
US20130090351A1 (en) 2013-04-11
US8779156B2 (en) 2014-07-15
AU2011232331A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
MX2012010918A (es) Analogos para el tratamiento o prevencion de infecciones por flavivirus.
MX2012007420A (es) Analogos para el tratamiento o prevencion de infecciones de flavivirus.
WO2011009084A3 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
PH12017501426A1 (en) Derivatives of betulin
HK1166788A1 (es)
SG178952A1 (en) Chemical compounds
IN2012DN01855A (es)
MX2012006026A (es) Derivados de acido 5-alquinil-tiofen-2-carboxilico y usos para tratamiento o prevencion de infecciones por flavivirus.
EA030189B8 (ru) Аналоги 2'-хлоронуклеозидов для инфекции вгс
MX2013006475A (es) Inhibidores macrociclicos de virus flaviviridae.
MD20140135A2 (ro) Inhibitori macrociclici ai viruşilor din familia Flaviviridae
NZ600817A (en) Inhibitors of flaviviridae viruses
NZ703064A (en) Inhibitors of hepatitis c virus
MX2012008221A (es) Inhibidores de virus flaviviridae.
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
NZ724503A (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703066A (en) Macrocyclic inhibitors of flaviviridae viruses
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
EA201290632A1 (ru) Производные бетулина
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
PH12015501560A1 (en) Heterocycle-substituted tetracyclic compounds and methods of use thereof for treatment of viral diseases
MX350746B (es) Derivados de ciclosporina novedosos para el tratamiento y la prevención de una infección viral.
WO2012009715A3 (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
MX2014009546A (es) Compuestos antivirales con una porcion heterotriciclica.
IN2014CN04449A (es)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal